Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Juntendo University Research: Omega-3 Fatty Acids Suppress Allergic Conjunctivitis Symptoms


News provided by

Juntendo University

04 Dec, 2018, 06:16 GMT

Share this article

Share toX

Share this article

Share toX

TOKYO, December 4, 2018 /PRNewswire/ --

Researchers at Juntendo University report in the FASEB Journal that a diet based on omega-3 fatty acids alleviates allergic conjunctivitis in mice. Their findings may lead to alternative treatments for the disease not based on traditional mast cell stabilizer and antihistamine eye drops.

Continue Reading
This image opens in the lightbox
Suppression mechanism of allergic conjunctivitis by an omega-3 fatty-acid diet in mice exposed to ragweed pollen. Mice on a diet A) without and B) with omega-3 fatty acids (PRNewsfoto/Juntendo University)
This image opens in the lightbox
Takehiko Yokomizu

     (Photo: https://mma.prnewswire.com/media/793322/Mice_Omega_3_Fatty_acid.jpg )

Related videos

Toshiaki Hirakata

https://youtu.be/Lywno38iXxg

Takehiko Yokomizo

https://youtu.be/SVDwYhYqkLM

Allergic conjunctivitis (AC) is a common eye disease, with symptoms including itch, redness of the conjunctiva (the membrane at the surface of the eye and eyelids) and discharge. The condition is usually treated by eye drops that often contain mast cell stabilizer and antihistamine, countering the action of histamine released in association with AC. Now, a team of researchers from Juntendo University led by Takehiko Yokomizo has shown that in mice, a diet rich in omega-3 fatty acids alleviates AC symptoms in the early and late phases of the disease. The scientists found that the omega-3 fatty acids reduce the amounts of certain inflammatory lipid mediators present in the conjunctiva and known to be involved in the pathogenesis of AC.

In the experiments of Yokomizo and colleagues, one group of mice was given food containing linseed oil, rich in an omega-3 fatty acid, while another group was kept on a diet based on soy oil, rich in an omega-6 fatty acid. After one month into the diet, the mice were sensitized with ragweed pollen through injection, and AC was induced by eyedrop containing ragweed pollen.  

The level of AC symptoms in the mice's eyes was summarized by a 'clinical score', factoring in swelling, redness and discharge. In addition, after the final application of pollen, scratching behavior was monitored - the mice were recorded on video. Eyeballs and blood were analyzed as well. The researchers observed that the omega-3 fatty-acid diet improved the allergic symptoms, including an almost complete suppression of scratching.

In order to gain insights into why omega-3 fatty acids alleviate AC symptoms, Yokomizo and colleagues analyzed which compounds are present in the conjunctiva. Specifically, they checked lipid mediators, and found that the amounts of particular inflammatory mediators were reduced.

The researchers also checked whether the diet affects the normal immune responses, known as Th2 responses, which trigger the release of histamine, and known to cause asthma and food allergies. By comparing the two groups of mice, they concluded that the Th2 response was comparable for both groups, and therefore not modulated by omega-3 fatty acids.

The Juntendo University scientists conclude that "altering the lipid mediator profile with dietary omega-3 fatty acids may be a safe and practical approach for the prevention and therapeutics of AC, especially given that omega-3 fatty acid consumption is currently declining worldwide".

Background  

Allergic conjunctivitis  

Allergic conjunctivitis (AC) is an eye inflammation caused by allergic reactions to pollen, mold spores or other substances. Eyes then become red, itchy, and watery. What happens is that the conjunctiva, the membrane covering the eyeball and the eyelids' insides, becomes irritated (swollen) from allergens. These symptoms result from the release of histamine and other substances, stimulating widening of blood vessels, irritation of nerve endings and increased production of tears. AC is quite common; 30-40% of the general population is affected by it.

Traditional treatment of AC is mainly by administering mast cell stabilizers and antihistamines, but Takehiko Yokomizo and colleagues from Juntendo University have now discovered that a diet of omega-3 fatty acids alleviates AC in a mouse model, without modulating the normal immune responses.

Omega-3 and omega-6 fatty acids  

Omega-3 and omega-6 fatty acids are organic molecules belonging to the category of polyunsaturated fatty acids. The term 'unsaturated' refers to double carbon bonds. In the case of omega-3 fatty acids, there is a (first) double bond between the third and the fourth carbon atom from the 'tail' end, in the case of omega-6 between the sixth and the seventh carbon atom from the tail.

Omega-3 and omega-6 fatty acids are commonly found in nutrients. Oily fish are a common source of omega-3, whereas omega-6 is present in food oils and nuts. The Western diet has evolved in such a way that many individuals now have an intake with a ratio of omega-6 to omega-3 of more than 10, whereas a ratio of 4 or lower is believed to be optimal.

The findings of Yokomizo and colleagues suggest that a diet rich in omega-3 fatty acids may alleviate the symptoms of allergic conjunctivitis in humans.

Reference  

Toshiaki Hirakata, Hyeon-Cheol Lee, Mai Ohba, Kazuko Saeki, Toshiaki Okuno, Akira Murakami, Akira Matsuda & Takehiko Yokomizo. Dietary omega-3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating Th2 immune responses. FASEB Journal, November 2018.

DOI: 10.1096/fj.201801805R

URL: https://www.fasebj.org/doi/abs/10.1096/fj.201801805R

Further information about Juntendo University

Mission Statement

The mission of Juntendo University is to strive for advances in society through education, research, and healthcare, guided by the motto "Jin - I exist as you exist" and the principle of "Fudan Zenshin - Continuously Moving Forward". The spirit of "Jin", which is the ideal of all those who gather at Juntendo University, entails being kind and considerate of others. The principle of "Fudan Zenshin" conveys the belief of the founders that education and research activities will only flourish in an environment of free competition. Our academic environment enables us to educate outstanding students to become healthcare professionals patients can believe in, scientists capable of innovative discoveries and inventions, and global citizens ready to serve society.

History of Juntendo University

Juntendo was originally founded in 1838 as a Dutch School of Medicine at a time when Western medical education was not yet embedded as a normal part of Japanese society. With the creation of Juntendo, the founders hoped to create a place where people could come together with the shared goal of helping society through the powers of medical education and practices. Their aspirations led to the establishment of Juntendo Hospital, the first private hospital in Japan. Through the years the institution's experience and perspective as an institution of higher education and a place of clinical practice has enabled Juntendo University to play an integral role in the shaping of Japanese medical education and practices. Along the way the focus of the institution has also expanded, now consisting of four undergraduate programs and three graduate programs, the university specializes in the fields of health and sports science and nursing health care and sciences, as well as medicine. Today, Juntendo University continues to pursue innovative approaches to international level education and research with the goal of applying the results to society.

Further information 
Juntendo University
2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421 JAPAN
E-mail: release@juntendo.ac.jp
Website: http://www.juntendo.ac.jp/english/
Research: https://www.juntendo.ac.jp/english/research.html

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.